Overview of Drug Product Development

Padma Narayan1

1 The Dow Chemical Company, Engineering Sciences, Solids Processing, Midland, Michigan
Publication Name:  Current Protocols in Pharmacology
Unit Number:  Unit 7.3
DOI:  10.1002/0471141755.ph0703s55
Online Posting Date:  December, 2011
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The process for developing drug delivery systems has evolved over the past two decades with more scientific rigor, involving a collaboration of various fields, i.e., biology, chemistry, engineering, and pharmaceutics. Drug products, also commonly known in the pharmaceutical industry as formulations or “dosage forms,” are used for administering the active pharmaceutical ingredient (API) for purposes of assessing safety in preclinical models, early‐ to late‐phase human clinical trials, and for routine clinical/commercial use. This overview discusses approaches for creating small‐molecule API dosage forms, from preformulation to commercial manufacturing. Curr. Protoc. Pharmacol. 55:7.3.1‐7.3.29. © 2011 by John Wiley & Sons, Inc.

Keywords: drug product development; pharmaceutical formulations; pharmaceutical development

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Delivery Pathways
  • Preformulation and Characterization
  • Preclinical Formulation Development
  • Drug Product Technologies
  • Clinical Formulation Development
  • Acknowledgements
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

   Alderborn, G. and Nystrom, C. (eds.) 1996. Pharmaceutical Powder Compaction Technology. Marcel Dekker, New York.
   Alsante, K.M., Ando, A., Brown, R., Ensing, J., Hatajik, T.D., Kong, W., and Tsuda, Y. 2007. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Del. Rev. 59:29‐37.
   Avdeef, A. 2007. Solubility of sparingly‐soluble ionizable drugs. Adv. Drug Del. Rev. 59:568‐590.
   Azarmi, S., Roa, W., and Lobenberg, R. 2007. Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm. 328:12‐21.
   Bakshi, M. and Singh, S. 2002. Development of validated stability‐indicating assay methods—critical review. J. Pharm. Biomed. Anal. 28:1011‐1040.
   Bedu‐Addo, F.K. 2004. Understanding lyophilization formulation development. Pharm. Technol. Lyophil. 10‐18.
   Bettinia, R., Catellania, P.L., Santia, P., Massimoa, G., Peppas, N.A., and Colomboa, P. 2001. Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate. J. Controlled Rel. 70:383‐391.
   Breitenbach, J. 2002. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54:107‐117.
   Brewster, M.E., Mackie, C., Noppe, M., Lampo, A., and Loftsson, T. 2007. The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines. Biotechnol. Pharm. Aspects Solvent Sys. Sel. Pharm. Biopharm. 6:221‐256.
   Callen, J.P. 2007. Complications and adverse reactions in the use of newer biologic agents. Sem. Cutan. Med. Surg. 26:6‐14.
   Cao, X., Morganti, M., Hancock, B.C., and Masterson, V.M. 2010. Correlating particle hardness with powder compaction performance. J. Pharm. Sci. 99:4307‐4316.
   Carson, J. and Wilms, H. 2006. Development of an international standard for shear testing. Powder Technol. 167:1‐9.
   Carstensen, J.T. 2000. Preformulation. In Drugs and the Pharmaceutical Sciences, Drug Stability 107 (C.T. Rhodes and J.T. Carstensen, eds.) pp. 237‐260. Informa Healthcare, New York.
   Cunningham, J.C., Winstead, D., and Zavaliangos, A. 2010. Understanding variation in roller compaction through finite element‐based process modeling. Computers Chem. Engin. 34:1058‐1071.
   Dai, W‐G. 2010. In vitro methods to assess drug precipitation. Int. J. Pharm. 393:1‐16.
   Darrington, R.T. and Jiao, J. 2004. Rapid and accurate prediction of degradant formation rates in pharmaceutical formulations using high‐performance liquid chromatography‐mass spectrometry. J. Pharm. Sci. 93:838‐846.
   Deng, T., Paul, K.A., Bradley, M.A., Immins, L., Preston, C., Scott, J., and Welfare, E.H. 2010. Investigations on air induced segregation of pharmaceutical powders and effect of material flow functions. Powder Technol. 203:354‐358.
   Feng, M.R., Lou, X., Brown, R.R., and Hutchaleelaha, A. 2000. Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics. Pharm. Res. 17:410‐418.
   Floyd, A. 1999. Top ten considerations in the development of parenteral emulsions. Pharm. Sci. Technol. Today 2:134‐143.
   Freisen, D.T, Shanker, R., Crew, M., Smithey, D.T., Curatolo, W.J., and Nightingale, J.A.S. 2008. Hydroxypropyl methylcellulose acetate succinate‐based spray‐dried dispersions: An overview. Mol. Pharm. 5:1003‐1019.
   Garcia‐Munoz, S., Dolph, S., and Ward, H.W II 2010. Handling uncertainty in the establishment of a design space for the manufacture of a pharmaceutical product. Computers Chem. Engin. 34:1098‐1107.
   Guzman, H.R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C.R., Chen, H., Moreau, J‐P., Almarsson, O., and Remenar, J. 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 96:2686‐2702.
   Hiestand, E.N. 1996. Rationale for and the measurement of tableting indices. In Pharmaceutical Powder Compaction Technology (G. Alderborn and C. Nystrom, Eds.) pp. 219‐244. Marcel Dekker, New York.
   Huang, J., Kaul, G., Cai, C., Chatlapalli, R., Hernandez‐Abad, P., Ghosh, K., and Nagi, A. 2009. Quality by design case study: An integrated multivariate approach to drug product and process development. Int. J. Pharm. 382:23‐32.
   Ishida, M., Abe, K., Hashizume, M., and Kawamura, M. 2008. A novel approach to sustained pseudoephedrine release: Differentially coated mini‐tablets in HPMC capsules. Int. J. Pharm. 359:46‐52.
   Jantratid, E., De Maiob, V., Rondab, E., Mattavelli, V., Vertzonic, M., and Dressman, J.B. 2009. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified‐release pellet dosage form. Eur. J. Pharm. Sci. 37:434‐441.
   Karande, P., Jain, A., and Mitragotri, S. 2006. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Controlled Rel. 115:85‐93.
   Kipp, J.E. 2007. Solubilizing systems for parenteral formulation development—small molecules. Biotechnol. Pharm. Aspects Solvent Sys. Sel. Pharm. Biopharm. 6:309‐339.
   Korsemeyer, R.W. and Peppas, N.A. 1981. Effect of the morphology of hydrophilic polymeric matrices on the diffusion and release of water soluble drugs. J. Membrane Sci. 9:211‐227.
   Krishna, G., Hodnick, W.F., Lang, W., Lin, X., Karra, S., Mao, J., and Almassian, B. 2001. Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M. AAPS PharmsciTech 2:1‐9.
   Lee, Y‐C., Zocharski, P.D., and Samas, B. 2003. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253:111‐119.
   Li, W., Bagnol, L., Berman, M., Chiarella, R.A, and Gerber, M. 2009. Applications of NIR in early stage formulation development. Part II. Content uniformity evaluation of low dose tablets by principal component analysis. Int. J. Pharm. 380:49‐54.
   Lindenberg, M., Kopp, S., and Dressman, J.B 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58:265‐278.
   Liu, F., Lizio, R., Meier, C., Petereit, H‐U., Blakey, P., and Basit, A.W. 2009. A novel concept in enteric coating: A double‐coating system providing rapid drug release in the proximal small intestine. J. Controlled Rel. 133:119‐124.
   Llinas, A. and Goodman, J.M. 2008. Polymorph control: past, present and future. Drug Disc. Today 13:198‐210.
   Malaterre, V., Ogorka, J., Loggia, N., and Gurny, R. 2009. Oral osmotically driven systems: 30 years of development and clinical use. Eur. J. Pharm. Biopharm. 73:311‐323.
   Mort, P.R. 2005. Scale‐up of binder agglomeration processes. Powder Technol. 150:86‐103.
   Mullarney, M.P. and Hancock, B.C. 2006. Mechanical property anisotropy of pharmaceutical excipient compacts. Int. J. Pharm. 314:9‐14.
   Ng, S‐F., Rouse, J., Sanderson, D., and Eccleston, G. 2010. A comparative study of transmembrane diffusion and permeation of ibuprofen across synthetic membranes using Franz diffusion cells. Pharmaceutics 2:209‐223.
   Nikowitz, K., Kása, P Jr., Pintye‐Hódi, K., and Regdon, G Jr. 2011. Study of the preparation of a multiparticulate drug delivery system with a layering technique. Powder Technol. 205:155‐159.
   Ozguney, I.S., Karasulu, H.Y., Kantarci, G., Sozer, S., Guneri, T. and Ertan, G. 2006. Transdermal delivery of diclofenac sodium through rat skin from various formulations. AAPS PharmSciTech 7:E1‐E7.
   Parkins, D.A. and Lashmar, U.T. 2000. The formulation of biopharmaceutical products. Pharm. Sci. Technol. Today 3:129‐137.
   Porter, C.J.H., Pouton, C.W., Cuine, J.F., and Charman, W.N. 2008. Enhancing intestinal drug solubilisation using lipid‐based delivery systems. Adv. Drug Deliv. Rev. 60:673‐691.
   Prausnitz, M.R. and Langer, R. 2008. Transdermal drug delivery. Nat. Biotechnol. 26:1261‐1268.
   Prpich, A., am Ende, M.T, Katzschner, T., Lubczyk, V., Weyhers, H., and Bernhard, G. 2010. Drug product modeling predictions for scale‐up of tablet film coating—A quality by design approach. Computers Chem. Engin. 34:1092‐1097.
   Qvist, M.H., Hoeck, U., Kreilgaard, B., Madsen, F., and Frokjaer, S. 2002. Release of chemical permeation enhancers from drug‐in‐adhesive transdermal patches. Int. J. Pharm. 231:253‐263.
   Rabinow, B.E. 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Disc. 3:785‐796.
   Richter, A., Olbrich, C., Krause, M., Hoffmann, J., and Kissel T. 2010. Polymeric micelles for parenteral delivery of sagopilone: Physicochemical characterization, novel formulation approaches and their toxicity assessment in vitro as well as in vivo. Eur. J. Pharm. Biopharm. 75:80‐89.
   Rowe, R.C. and Roberts, R.J. 1996. Mechanical Properties. In Pharmaceutical Powder Compaction Technology (G. Alderborn and C. Nystrom, Eds.) pp. 283‐322. Marcel Dekker, New York.
   Schulze, D. 2011. Round robin test on ring shear testers. Adv. Powder Technol. 22:197‐202.
   Sekulic, S.S., Wakeman, J., Doherty, P., and Hailey, P.A. 1998. Automated system for the on‐line monitoring of powder blending processes using near‐infrared spectroscopy Part II. Qualitative approaches to blend evaluation. J. Pharm. Biomed. Anal. 17:1285‐1309.
   Serajuddin, A.T.M. 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59:603‐616.
   Shahrokh, Z. 2007. Aqueous solubilizing systems for parenteral formulation development—proteins. Biotechnol. Pharm. Aspects Solvent Sys. Sel. Pharm. Biopharm. 6:341‐357.
   Shire, S.J. 2009. Formulation and manufacturability of biologics. Curr. Opin. Biotechnol. 20:708‐714.
   Solomun, L., Ibric, S., Boltic, Z., Djuric, Z., and Stupara, B. 2008. The impact of primary packaging on the quality of parenteral products. J. Pharm. Biomed. Anal. 48:744‐748.
   Strickley, R.G. and Oliyai, R. 2007. Formulation challenges of prodrugs. Biotechnol. Pharm. Aspects 5:384‐410.
   Tan, H.S. and Pfister, W.R. 1999. Pressure‐sensitive adhesives for transdermal drug delivery systems. Pharm. Sci. Technol. Today 2:60‐69.
   Trevaskis, N.L., Charman, W.L., and Porter, C.J.H. 2008. Lipid‐based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv. Drug Deliv. Rev. 60:702‐716.
   Van Buskirk, G.A., Gonzalez, M.A., Shah, V.P., Barnhardt, S., Barrett, C., Berge, S., Cleary, G., Chan, K., Flynn, G., Foster, T., Gale, R., Garrison, R., Gochnour, S., Gotto, A., Govil, S., Gray, V.A., Hammar, J., Harder, S., Hoiberg, C., Hussain, A., Karp, C., Llanos, H., Mantelle, J., Noonan, P., Swanson, D., and Zerbe, H. 1997. Scale‐up of adhesive transdermal drug delivery systems. Eur. J. Pharm. Biopharm. 44:327‐331.
   Wang Y., Thakura, R., Fan, Q., and Michniakc, B. 2005. Transdermal iontophoresis: Combination strategies to improve transdermal iontophoretic drug delivery. Eur. J. Pharm. Biopharm. 60:179‐191.
   Ward, J., Buckle, P., and Clarkson, P.J. 2010. Designing packaging to support the safe use of medicines at home. Appl. Ergonomics 41:682‐694.
   Waterman, K.C. and Adami, R.C. 2005. Accelerated aging: Prediction of chemical stability of Pharmaceuticals. Int. J. Pharm. 293:101‐125.
   Waterman, K.C. and MacDonald, B.C. 2010. Package selection for moisture protection for solid oral drug products. J. Pharm. Sci. 99:4437‐4452.
   Waterman, K.C., Adami, R.C., Alsante, K.M, Antipas, A.S, Arenson, D.R., Carrier, R, Hong, J., Landis, M.S., Lombardo, F., Shah, J.C., Shalaev, E., Smith, S.W., and Wang, H. 2002a. Hydrolysis in pharmaceutical formulations. Pharm. Devel. Technol. 7:113‐146.
   Waterman, K.C., Adami, R.C., Alsante, K.M., Hong, J., Landis, M.S, Lombardo, F., and Roberts, C.J. 2002b. Stabilization of pharmaceuticals to oxidative degradation. Pharm. Devel. Technol. 7:1‐32.
   Waterman, K.C., MacDonald, B.C., and Roy, M.C. 2009. Extrudable core system: Development of a single‐layer osmotic controlled‐release tablet. J. Controlled Rel. 134:201‐206.
   Wilding, I.R, Hardy, J.G., Maccari, M., Ravelli, V. and Davis, S.S. 1991. Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazem. Int. J. Pharm. 76:133‐143.
   Wu, H., Heilweil, E., Hussain, A.S., and Khan, M.A. 2007. Process analytical technology (PAT): Effects of instrumental and compositional variables on terahertz spectral data quality to characterize pharmaceutical materials and tablets. Int. J. Pharm. 343:148‐158.
   Zakeri‐Milani, P., Barzegar‐Jalali, M., Azimi, M., and Valizadeh, H. 2009. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur. J. Pharm. Biopharm. 73:102‐106.
   Zinchuk, A.V., Mullarney, M.P., and Hancock, B.C. 2004. Simulation of roller compaction using a laboratory scale compaction simulator. Int. J. Pharm. 269:403‐415.
Guidance Documents/Web Sites
   Center for Drug Evaluation and Research (CDER). November 1995. Guidance for Industry: Immediate Release Solid Oral Dosage Forms Scale‐Up and Post‐approval Changes (SUPAC): Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. U.S. Food and Drug Administration.
   Center for Drug Evaluation and Research (CDER). September 1997. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. U.S. Food and Drug Administration.
   Center for Drug Evaluation and Research (CDER). August 2000. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate‐Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. U.S. Food and Drug Administration.
  Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), and Office of Regulatory Affairs (ORA). September 2004. Guidance for Industry: PAT‐ A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. Food and Drug Administration.
   Office of Combination Products. September 2006. Guidance for Industry and FDA Staff: Early Development Considerations for Innovative Combination Products. U.S. Food and Drug Administration.
  Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). June 2008. Guidance for Industry: ICH Q3A Impurities in New Drug Substances. U.S. Food and Drug Administration.
  Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). November 2009. Guidance for Industry: ICH Q8(R2) Pharmaceutical Development. U.S. Food and Drug Administration.
  Center for Drug Evaluation and Research (CDER) and Center for Drug Evaluation and Research (CBER). January 2010. Guidance for Industry: ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. U.S. Food and Drug Administration.
  FDA Web site: http://www.fda.gov.
  USP Web site: http://www.usp.org.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library